Scholar Rock – Talk Bio

Scholar Rock’s SMA drug helps Zepbound patients retain muscle in phase 2 trial

1 month ago talkbio0Tagged apitegromab, GDF8 protein, human, Inhibitor, Lean Mass, muscle preservation, Obesity, Phase 2 trial, Scholar Rock, Spinal Muscular Atrophy, Weight Loss, Zepbound

Scholar Rock; apitegromab; SMA drug; Zepbound; tirzepatide; muscle preservation; obesity; weight loss; phase 2 trial; lean mass; myostatin inhibitor

Novo Nordisk CEO Departs Amid Weight-Loss Drug Market Pressures; Flagship Biotech Appoints CEO from Scholar Rock

2 months ago talkbio0Tagged Appointments, biotech, CEO, Challenge, departure - ActRelationshipType, Eli Lilly competition, Flagship, Lars Fruergaard Jørgensen, Market, Nordisk, Obesity, Scholar Rock

Novo Nordisk; CEO departure; Lars Fruergaard Jørgensen; obesity drugs; weight-loss market; Eli Lilly competition; market challenges; Flagship Biotech; CEO appointment; Scholar Rock

Scholar Rock Seeks $275M Funding Following Successful SMA Therapy Trial

10 months ago talkbio0Tagged Clinical Trials, pipeline, reshuffle, Scholar Rock, SMA, Spinal Muscular Atrophy, Vincerx

Scholar Rock, funding, SMA therapy, clinical trial, Vincerx, pipeline reshuffle

Scholar Rock’s Stock Skyrockets 300% Following Successful Phase III Trial of Apitegromab for Spinal Muscular Atrophy

10 months ago talkbio0Tagged apitegromab, Biologics License Application, MAA, Phase 3 Clinical Trials, Scholar Rock, SMA, Spinal Muscular Atrophy, Stock Surge

Scholar Rock, Spinal Muscular Atrophy (SMA), Apitegromab, Phase III Trial, Stock Surge, Biologics License Application (BLA), Marketing Authorisation Application (MAA)